CLINICAL MANIFESTATIONS OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY AND MODERN ANALYSIS OF RISK FACTORS IN PEDIATRIC PRACTICE

International Journal of Cognitive Neuroscience and Psychology

View Article

Keywords

progressive multifocal leukoencephalopathy
children
JC virus

How to Cite

Imomnazarovna, K. D., & Toshtemirovich, N. S. (2025). CLINICAL MANIFESTATIONS OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY AND MODERN ANALYSIS OF RISK FACTORS IN PEDIATRIC PRACTICE. International Journal of Cognitive Neuroscience and Psychology, 3(9), 105–109. Retrieved from https://medicaljournals.eu/index.php/IJCNP/article/view/2150

Abstract

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system caused by JC virus (JCV), mainly observed in immunodeficient conditions. This neuroinfection is considered a severe pathology with a high probability of leading to death.

View Article

References

1. Åström, K. E. Progressive multifocal leukoencephalopathy: a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease / K. E. Åström, E. L. Mancall, E. P. Richardson // Brain. – 1958. – Vol. 81, № 1. – P. 93–111.

2. Richardson, K. Progressive multifocal leukoencephalopathy in children: clinical and radiological features / K. Richardson, S. M. Peters // Pediatric Neurology. – 1995. – Vol. 12, № 3. – P. 207–212.

3. Berger, J. R. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease / J. R. Berger, L. Houff // Nature Reviews Neurology. – 2019. – Vol. 15, № 6. – P. 313–327.

4. Cortese, I. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related neurological disease / I. Cortese, D. S. Reich // Nature Reviews Neurology. – 2021. – Vol. 17, № 1. – P. 37–51.

5. Gheuens, S. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression / S. Gheuens, G. Pierone, P. Peeters // Journal of Neurovirology. – 2020. – Vol. 26, № 1. – P. 1–18.

6. Williamson, E. M. JC virus infection in the setting of prophylactic treatment of multiple sclerosis / E. M. Williamson, J. R. Berger // Multiple Sclerosis Journal. – 2018. – Vol. 24, № 6. – P. 737–744.

7. Brew, B. J. Progressive multifocal leukoencephalopathy after natalizumab therapy: clinical and MRI course / B. J. Brew, S. J. Davies, P. Cinque // Annals of Neurology. – 2020. – Vol. 87, № 5. – P. 671–685.

8. Miskin, D. P. Diagnosis of Progressive Multifocal Leukoencephalopathy: comparative analysis of cerebrospinal fluid and plasma JC virus PCR assays / D. P. Miskin, R. Koralnik // Journal of Infectious Diseases. – 2019. – Vol. 219, № 7. – P. 1057–1067.

9. Monaco, M. C. JC virus infection of meningeal and choroidal epithelial cells in patients with progressive multifocal leukoencephalopathy / M. C. Monaco, B. E. Sabath, L. M. Durham // Journal of Virology. – 2018. – Vol. 92, № 17. – P. e00275-18.

10. Pavlovic, D. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives / D. Pavlovic, D. C. Patera, F. Nyberg // Therapeutic Advances in Neurological Disorders. – 2021. – Vol. 14. – P. 1756286421998899.

11. Schwab, N. PML risk stratification using anti-JCV antibody index and L-selectin / N. Schwab, C. Schneider-Hohendorf, H. Wiendl // Multiple Sclerosis Journal. – 2020. – Vol. 26, № 14. – P. 1848–1858.

12. European Federation of Neurological Societies. EFNS guidelines on diagnosis and management of progressive multifocal leukoencephalopathy / EFNS Scientific Panel on Infectious Diseases // European Journal of Neurology. – 2019. – Vol. 26, № 6. – P. 854–865.